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Abstract
Background: The treatment of hepatocellular carcinoma (HCC) is still a major health issue 
because of its increasing incidence and because of the complexity of its management. Tran-
sarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used 
locoregional therapies in the treatment of HCC, especially for unresectable intermediate and 
advanced HCCs. Summary: The modern use of TAE and TACE opens new scenarios for the 
treatment of unresectable HCC and has yielded interesting results. The present work de-
scribes the role of transarterial therapies for HCC and focuses on the different Western and 
Eastern approaches to the study of response predictors. Key Messages: Recent refinements 
in interventional radiology techniques and in HCC patient selection have facilitated better 
local control of the disease. The molecular profiling of HCC to predict the response to TACE 
and TAE will greatly help clinicians identify the optimum therapy.
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IntroductionTransarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of hepatocellular carcinoma (HCC), es-pecially for unresectable intermediate and advanced HCCs [1]. Although TAE and TACE are considered to be noncurative therapies, for patients with advanced HCC, no other therapy is usually recommended when surgery, percutaneous ablation, and sorafenib are unfeasible. Transarterial radioembolization (TARE) is an emerging modality that has achieved promis-ing results for intermediate and advanced HCC [2]. The present work describes the role of transarterial therapies for HCC, starting with the techniques themselves and then focusing on the predictors of response.
TACE for HCCThe HCC vasculature is supplied by the hepatic artery rather than by the portal vein. Consequently, the segmental hepatic arteries may be selectively catheterized via retrograde femoral access, and the tumor can be visualized by means of superselective angiography. Then, different embolic agents can be injected with the aim of obliterating the vascular sup-ply to the tumor and/or delivering drugs/radioisotopes, thereby halting or slowing tumor progression.Liver embolization for HCC is commonly used in two main settings: (1) large unresect-able HCCs unsuitable for surgery or ablation, and (2) prior to resection or to liver transplan-tation as a bridge therapy. In general, the best candidates are those patients with unresect-able lesions without vascular invasion or extrahepatic spread and with well-preserved liver function.Although there is no standard technique for HCC embolization, two main approaches are traditionally recognized: TACE and TAE [3]. A third, more recent and promising tech-nique is TARE, which delivers to the tumor radioactive isotopes (eg, iodine-131-labeled lipi-odol or yttrium-90 [90-Y]-tagged glass or resin microspheres).
The goal of TACE is to fill the tumor with a chemotherapeutic drug (eg, doxorubicin, epirubicin, cisplatin, or mitomycin C) using a carrier agent. Historically, the carrier agent was Lipiodol, but this has been largely replaced by drug-eluting beads TACE, which are available in different sizes [3–9]. The use of a chemotherapeutic agent requires preventive medica-tion to avoid drug-related side effects [10]. In contrast, TAE aims to achieve superselective 
vascular embolization using gelatin sponge, Lipiodol, or microparticles as small as 40 μm in diameter [11]. No drugs are injected during TAE, and recent evidence has suggested that no 
survival benefit is derived by the use of chemotherapy in TACE versus TAE [12]. In contrast to TAE and TACE, TARE achieves cell death by local radiation damage; TARE is thus considered 
to be a form of brachytherapy with no significant embolic effect. TARE using 90-Y-tagged glass beads has been shown to be safe and probably effective in patients with unresectable 
HCC [13–15]. A recent meta-analysis suggested that TARE is significantly better than TACE in terms of survival, time to progression, hospitalization time, and complication rates for patients with HCC [16]. A further role of TARE in advanced HCC patients is as a conversion treatment for patients considered otherwise unresectable or even as a bridge to transplan-tation [17]. Moreover, in HCC patients with a future remnant liver (FRL) inadequate for up-front surgery, TARE may represent a surrogate for portal vein embolization, combining FRL hypertrophy and tumor treatment [18].In the HCC setting, the degree of survival advantage offered by TAE/TACE versus medi-cal therapy is still a matter of debate. Two controlled trials have shown a survival advantage 
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for TACE compared with symptomatic treatment alone in selected patients with unresectable HCC and preserved liver function [19, 20]; however, a more recent Cochrane meta-analysis 
failed to find evidence of a survival benefit [20]. Table 1 details the results of a literature re-view on TAE for HCC.An unresolved issue in the treatment of HCC with TACE/TAE is the timing of repeat treat-
ment. In clinical practice, it remains difficult to predict the failure of such retreatments. More-
over, even the definition of refractory TACE/TAE is still unclear. To address this problem, scor-
ing systems have been proposed to help physicians to identify patients who will not profit from retreatment with TACE. Among these scores, the assessment for retreatment with TACE 
score seems to be one of the most promising [21]. The accurate review of the imaging findings after TAE/TACE still remains one of the most important steps in interpreting the results of the procedures [22].Another important open issue in the treatment of HCC with TACE/TAE is the association between these therapies and sorafenib. Recently, Lencioni et al. [23] reported that the use of TACE with doxorubicin-eluting beads plus sorafenib did not improve patient survival over 
TACE alone. Despite these negative results, further studies on the benefit of combined therapy should be undertaken.Complications from liver embolization may include upper quadrant pain, nausea, moder-ate ileus, fatigue, fever, and transient elevations of asparate aminotransferase, alanine ami-notransferase, and bilirubin levels. Symptoms are usually self-limiting and may be worsened by the use of chemotherapy in TACE [20, 24]. Serious complications such as hepatic failure, gastroduodenal ulceration, kidney failure, and death (2–3%) have been reported at very low percentages [3].
Table 1. Essential literature review on transarterial embolization for HCCAuthor, Year Treatment Summary Main findingsSalem et al., 2010  [13] TARE 291 patients with HCC treated  with 90Y radioembolization Response rates 42% (WHO criteria) and 57% (EASL criteria) Time to progression and overall survival varied by tumor stage and liver functionMazzaferro et al., 2013  [14] TARE 52 patients with intermediate to advanced HCC Prospective, phase II study Median time to progression 11 months (no difference between portal vein thrombosis vs. no portal vein thrombosis) Median overall survival 15 months  Various grades of reduced liver  function in 36.5% within 6 monthsLlovet et al., 2002  [18] TACE 112 patients with unresectable  HCC Randomized controlled trial 3 treatment arms: TAE, TACE, and symptomatic treatment
TACE improved survival of strin-gently selected patients
Lo et al., 2002  [19] TACE 80 patients with unresectable  HCC Randomized controlled trial TACE vs. symptomatic treatment
TACE significantly improved  survival in select patients
WHO=World Health Organization; EASL=European Association for the Study of the Liver. 
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Predictors of Response to TACE/TAE Treatments: The Western PerspectiveTACE and TAE promote local disease control through tumor necrosis and apoptosis in-duced by hypoxic and cytotoxic agents. Although potentially very useful in optimizing patient selection and follow-up, the individual response to TACE is generally unpredictable [19]. In-vestigators from both Eastern and Western countries have proposed several prognostic in-dices, based on combinations of clinical and laboratory parameters, to help clinicians select appropriate candidates for initial or repeat TACE or TAE. Unfortunately, no prognostic index 
is today universally accepted because they are difficult to implement, insufficiently discrimi-natory, or present methodological problems [25]. Such studies essentially identify a set of parameters that appear to maximize predictive performance, but this predictive perfor-
mance cannot be repeated elsewhere because of random fluctuations of patient character-istics and differences in clinical management and the technical execution of TACE and TAE. This fact suggests that studies with larger target populations are needed [25]. Moreover, the sensitivity of HCC to transarterial therapy may also vary according to the tumor biology, but very few studies have focused on the predictive value of tumor morphological or molecular markers of response to TACE or TAE.A study conducted in Italy and France investigated the association of post-TACE tumor necrosis, as assessed in surgical specimens, with the immunohistochemical expression of biomarkers involved in adaptive mechanisms to hypoxia that are hypothetically able to in-
fluence the response to TACE [26]. The markers selected in this study were hypoxia-induc-
ible factor 1-α (HIF1α) and vascular endothelial growth factor (VEGF) for neoangiogenesis, CD34 for microvessel density, CA9 for antiapoptotic activity, CD133 and nestin for stem cell features, and vimentin and E-cadherin for the epithelial–mesenchymal transition (EMT); all 
these markers have previously been identified as being related to treatment resistance in several types of malignancies [27–30]. In the above study, multivariate analysis found that 
only CD34 and VEGF retained a significant association with TACE response [26]. A typical 
pattern of expression (VEGF–, CD34+) was associated with resistance to TACE, suggesting that HCCs with this expression pattern are more resistant to hypoxia because they have al-ready developed a complete vascular network (increased CD34) without requiring further 
neoangiogenesis (decreased VEGF). This finding was also confirmed based on the results of pretreatment liver biopsies and their correlation with the radiological evaluation of re-sponses to TACE.These data suggest that further investigations are needed on the role of HCC biology 
in influencing responses to TACE, in particular because easily applicable and validated pre-dictors of response to treatment are currently lacking. Prototypical characteristics of these markers have recently been proposed: ideally, they should be cost-effective, reproducible, and easy to evaluate also on pretreatment specimens, such as liver biopsy or liquid biopsy specimens [31].
Predictors of Response to Intra-Arterial Treatment: The Eastern PerspectiveTACE induces marked ischemic tumor necrosis by obstructing tumor-feeding arteries 
with a chemotherapeutic agent emulsified with Lipiodol and embolic agents. However, a sig-
nificant number (50–86%) of HCCs show residual viable tumor [32]. To adapt and survive in a hypoxic tumor microenvironment, cancer cells express hypoxia-inducible factors, includ-
ing HIF1α, to activate target genes involved in proliferation, angiogenesis, and EMT, resulting in a more aggressive tumor phenotype [33]. Hypoxia is reportedly  important in reprogram-ming cancer cells to a cancer stem cell phenotype, which plays an important role in tumor 
Lanza et al.: TAE and TACE for HCC
Liver Cancer 2017;6:27–33
DOI: 10.1159/000449347
Published online: November 29, 2016
© 2016 S. Karger AG, Basel
www.karger.com/lic
31
maintenance and recurrence [34]. HCCs that express stemness-related markers, such as K19, EpCAM, or CD133, are known to have aggressive biological behavior with poorer prognosis compared to HCCs not expressing these markers [35]. Hepatitis B virus (HBV) is the main etiology of HCC in Eastern countries, and, recently, Hepatitis B protein x (HBx) antigen was 
reported to enhance hypoxia signaling through HIF1α activation and to enhance EpCAM ex-
pression by activating β-catenin and regulating EpCAM promoter methylation [35]. Thus, HBx is suggested to be an additional player in the promotion of the switch in gene expression to stemness in hepatocarcinogenesis, especially in hypoxic tumor microenvironments.To study the effect of stemness on the TACE response, the authors (HR and YNP) evalu-ated the transcript levels of hypoxia- (HIF1A), stemness- (EPCAM, KRT19, POU5F1, NANOG), and EMT-related (SNAI1, TWIST1) markers by real-time reverse-transcription polymerase chain reaction in HBV-related progressed HCCs that had and had not undergone preopera-tive TACE; totally necrotic HCCs after TACE were excluded [unpublished data]. Residual HCCs that had undergone preoperative TACE exhibited upregulation of HIF1A and SNAI1 mRNA compared to those that had not undergone preoperative TACE. HCCs with high HIF1A mRNA levels showed greater transcription levels of stemness- and EMT-related markers, more in-vasive pathological features, and poorer outcomes than those with low HIF1A mRNA levels. Therefore, stemness is considered to be involved with TACE resistance via upregulation of 
HIF1A. Consequently, controlling stemness is suggested to be important to increase the TACE 
response of HBV-related HCC. Further studies are needed to validate and confirm our findings.
Conclusions
TACE and TAE are two widely used therapies for HCC. Recent refinements in interven-tional radiology techniques have facilitated better local control, and TARE is rapidly emerging as an alternative therapy, thereby further expanding the indications for intra-arterial thera-
pies. Further refinement of the patient selection criteria will optimize the use and role of such 
treatments. In the future, the molecular profiling of HCC to predict the response to TACE and TAE will help clinicians select the optimum treatment.
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